White & Case (New York)

Kevin Adam

White & Case (New York)
Lawyer (Associate)

Kevin Adam is a litigation associate in the New York and Boston offices and a member of the firm’s Global Competition Group. His practice focuses on complex litigation in the areas of antitrust, intellectual property, and commercial disputes. Kevin represents several leading global pharmaceutical companies, including Allergan and Boehringer Ingelheim, in class action litigation matters at the cutting edge of antitrust and intellectual property, including AGGRENOX®, BOTOX®, DORYX®, NAMENDA®, and ASACOL®. He also has experience advising clients in the aviation and casino industries. Kevin regularly speaks and writes about antitrust, class actions, and intellectual property. He has published a number of articles in those areas and is a co-author of a book on class actions titled "Deconstructing Rule 23: A Comparison of Massachusetts and Federal Class-Action Litigation."

Distinctions

Linked authors

White & Case (Brussels)
White & Case (Washington)
White & Case (Washington)
White & Case (New York)
White & Case (Brussels)

Articles

864 Bulletin

Michael Gallagher, Kristen O’Shaughnessy, Kathryn Jordan Mims, Kevin Adam, Jaclyn Phillips The US President Joe Biden publishes an executive order containing 72 initiatives to address competition concerns in several industries, including pharmaceuticals, biotech, and healthcare

277

Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number of industries, including pharmaceuticals, biotech, and healthcare. In (...)

Mark J. Gidley, George Paul, Jack E. Pace, Kathryn Jordan Mims, Kristen O’Shaughnessy, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Erin McNamee The US President Joe Biden signs an executive order instructing more than a dozen federal agencies to promptly tackle some of the most pressing competition problems across the national economy

223

A new Executive Order signed by President Biden includes 72 initiatives instructing more than a dozen federal agencies, including the US Department of Justice and the Federal Trade Commission, to, according to the White House’s Fact Sheet, "promptly tackle some of the most pressing competition (...)

Jack E. Pace, Kristen O’Shaughnessy, Robert Milne, Peter J. Carney, Michael Gallagher, Mark J. Gidley, Kevin Adam The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing

144

What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new (...)

Michael E. Hamburger, Kevin Adam, Abdul Hafiz The US Court of Appeals for the First Circuit holds that no class containing uninjured members can be certified unless, when moving for class certification, plaintiffs offer a manageable way for defendants to contest at trial whether their conduct injured individual class members (In re: Asacol Antitrust Litigation)

50

The U.S. Court of Appeals for the First Circuit’s landmark In re: Asacol Antitrust Litigation decision holds that no class containing uninjured members can be certified unless, when moving for class certification, plaintiffs offer a manageable way for defendants to contest at trial whether their (...)

Send a message